SLC-3010 for Solid Tumors, Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Karmanos Cancer Institute, Detroit, MI
Solid Tumors, Advanced Solid Tumors
SLC-3010 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Solid Tumors, Advanced Solid Tumors

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 30 days after last dose

Day 30
Occurrence of DLTs

Trial Safety

Safety Progress

1 of 3

Other trials for Solid Tumors, Advanced Solid Tumors

Trial Design

2 Treatment Groups

Gemcitabine combination
1 of 2
Monotherapy
1 of 2
Experimental Treatment

420 Total Participants · 2 Treatment Groups

Primary Treatment: SLC-3010 · No Placebo Group · Phase 1 & 2

Gemcitabine combinationExperimental Group · 2 Interventions: SLC-3010, Gemcitabine · Intervention Types: Drug, CombinationProduct
Monotherapy
Drug
Experimental Group · 1 Intervention: SLC-3010 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gemcitabine
2017
Completed Phase 3
~2940

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days after last dose
Closest Location: Karmanos Cancer Institute · Detroit, MI
Photo of karmanos cancer institute 1Photo of Karmanos Cancer Institute 2Photo of mi barbara ann karmanos cancer institute 3
2008First Recorded Clinical Trial
15 TrialsResearching Solid Tumors, Advanced Solid Tumors
234 CompletedClinical Trials

Who is running the clinical trial?

SelecxineLead Sponsor
Sunmi ShinStudy DirectorProject Manager

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a solid tumor and you have not responded to standard therapy

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.